Characterization of novel mouse esophageal squamous cell carcinoma cell lines and their utility as preclinical models
- 28 February 2025
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 616, 217600
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Overactivation of XBP1 in plasma cells implies worse survival through innate immunity in esophageal squamous cell carcinomaCancer Letters, 2024
- The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinomaCancer Letters, 2024
- Synergistic effects of Ω-3 polyunsaturated fatty acid supplementation and programmed cell death protein 1 blockade on tumor growth and immune modulation in a xenograft model of esophageal cancerClinical Nutrition ESPEN, 2024
- Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarizationCancer Letters, 2024
- Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinomaCancer Cell, 2023
- Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progressionCancer Letters, 2023
- Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinomaCancer Cell, 2022
- Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolutionCancer Letters, 2022
- Advances and challenges in the treatment of esophageal cancerActa Pharmaceutica Sinica B, 2021
- A new mouse esophageal cancer cell line (mEC25)‐derived pre‐clinical syngeneic tumor model for immunotherapyCancer Communications, 2020